Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


16.07.2018

1 Am J Respir Crit Care Med
2 Ann Oncol
1 Ann Surg
1 Clin Lung Cancer
2 Int J Cancer
4 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Nucl Med
7 J Thorac Oncol
1 JAMA Oncol
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. RIVERA MP, Tanner NT, Silvestri GA, Detterbeck FC, et al
    Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement.
    Am J Respir Crit Care Med. 2018;198:e3-e13.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. COTTRELL TR, Thompson ED, Forde PM, Stein JE, et al
    Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).
    Ann Oncol. 2018 Jul 6. pii: 5049993. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048419. doi: 10.1093.
    PubMed     Text format    


    Ann Surg

  4. MCMURRY TL, Stukenborg GJ, Kessler LG, Colditz GA, et al
    More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study.
    Ann Surg. 2018 Jul 12. doi: 10.1097/SLA.0000000000002955.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  5. ARUNACHALAM A, Li H, Bittoni MA, Camacho R, et al
    Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Jun 6. pii: S1525-7304(18)30136.
    PubMed     Text format     Abstract available


    Int J Cancer

  6. XU Y, Liu H, Liu S, Wang Y, et al
    Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31660.
    PubMed     Text format     Abstract available

  7. YUAN Q, Chen X, Han Y, Lei T, et al
    Modification of alpha2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31737.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  8. PETTY WJ, Urbanic JJ, Ahmed T, Hughes R, et al
    Long Term Outcomes of a Phase II Trial of Chemotherapy with Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Jul 9. pii: S0360-3016(18)31401.
    PubMed     Text format     Abstract available

  9. BOONYAWAN K, Gomez DR, Komaki R, Xu Y, et al
    Clinical and Dosimetric Factors Predicting Grade >/=2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
    Int J Radiat Oncol Biol Phys. 2018;101:919-926.
    PubMed     Text format     Abstract available

  10. TORRE-BOUSCOULET L, Arroyo-Hernandez M, Martinez-Briseno D, Munoz-Montano WR, et al
    Longitudinal Evaluation of Lung Function in Patients With Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy.
    Int J Radiat Oncol Biol Phys. 2018;101:910-918.
    PubMed     Text format     Abstract available

  11. BRADE AM, Wenz F, Koppe F, Lievens Y, et al
    Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial.
    Int J Radiat Oncol Biol Phys. 2018;101:927-934.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  12. YANG J, Zhang Y, Sun X, Gusdon AM, et al
    The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study.
    J Cancer Res Clin Oncol. 2018 Jul 12. pii: 10.1007/s00432-018-2702.
    PubMed     Text format     Abstract available


    J Nucl Med

  13. DE BRUYCKER S, Vangestel C, Van den Wyngaert T, Pauwels P, et al
    (18)F-HX4 Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy.
    J Nucl Med. 2018 Jul 6. pii: jnumed.118.212225. doi: 10.2967/jnumed.118.212225.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  14. LIU Y, Lusk CM, Cho MH, Silverman EK, et al
    Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
    PubMed     Text format     Abstract available

  15. KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
    Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
    PubMed     Text format     Abstract available

  16. SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
    Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
    PubMed     Text format    

  17. PATIL T, Smith DE, Bunn PA, Aisner DL, et al
    The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
    PubMed     Text format     Abstract available

  18. WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
    A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
    PubMed     Text format     Abstract available

  19. RIESS JW, Gandara DR, Frampton GM, Madison R, et al
    Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
    PubMed     Text format     Abstract available

  20. OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
    Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
    PubMed     Text format     Abstract available


    JAMA Oncol

  21. GUIDA F, Sun N, Bantis LE, Muller DC, et al
    Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
    PubMed     Text format     Abstract available


    PLoS One

  22. LIM JU, Yeo CD, Kang HS, Park CK, et al
    Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
    PLoS One. 2018;13:e0200341.
    PubMed     Text format     Abstract available

  23. DUAN L, Ye L, Zhuang L, Zou X, et al
    VEGFC/VEGFR3 axis mediates TGFbeta1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cells.
    PLoS One. 2018;13:e0200452.
    PubMed     Text format     Abstract available

  24. LU X, Gao J, Zhang Y, Zhao T, et al
    CTEN induces epithelial-mesenchymal transition (EMT) and metastasis in non small cell lung cancer cells.
    PLoS One. 2018;13:e0198823.
    PubMed     Text format     Abstract available

  25. PANNUTI A, Filipovic A, Hicks C, Lefkowitz E, et al
    Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.
    PLoS One. 2018;13:e0194790.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: